Psychiatric Multi-omics and Neuroimaging Project
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age13-35
Sponsormingjun Zhong
About this trial
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
Eligibility criteria
Qualifiers
Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
Course of disease: <24 months
Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
No nuclear magnetic contraindications.
Disqualifiers
Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
Have a major physical disease or infectious disease
History of coma and serious neurological disease 4.MRI contraindications.
Trial design
Treatments tested in this trial
- Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Treatment groups
1,899 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
mingjun Zhong
Lead sponsor
Second Xiangya Hospital of Central South University
Sponsor institution
Source ClinicalTrials.gov